Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Open accessThe DOI matches its Crossref record; 230 of the 235 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and have long been considered incurable. Following the successful development of a gene augmentation therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different therapeutic approaches are currently being developed, in particular a large variety of molecular therapies. These are depending on the severity of the retinal degeneration, knowledge of the pathophysiological mechanism underlying each subtype of IRD, and the therapeutic target molecule. DNA therapies include approaches such as gene augmentation therapy, genome editing and optogenetics. For some genetic subtypes of IRD, RNA therapies and compound therapies have also shown considerable therapeutic potential. In this review, we summarize the current state-of-the-art of various therapeutic approaches, including the pros and cons of each strategy, and outline the future challenges that lie ahead in the combat against IRDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, another large gene, CEP290, can be rescued on the mRNA level by antisense oligonucleotides (AONs; QR-110 for Leber congenital amaurosis (LCA), with CEP290; QR-421a for LCA with USH2A) [19].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Neurodegenerative Disorders: Parkinson's Disease and Huntington's Disease
Hague, S., Klaffke, S., & Bandmann, O. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948961_0007 · Cited by 2,767
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414 · cited 1×
“To overcome this aspect, researchers have developed different strategies—(i) using ribonucleoproteins (RNPs) as a form of delivery [55]; (ii) titrating the concentration of gRNA and Cas9 or using two gRNAs flanking the target region [56]; (iii) adding two additional guanine bases at the 5’ end of the gRNA sequence for…”
BackgroundRNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017) · Science · doi:10.1126/science.aaq0180 · Cited by 1,834
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 2×
“The big advantage of the mRNA platform is that it does not require delivery into the nucleus and the risk of integration into the host genome is reduced [24,25].”
Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Foroozandeh, P., & Aziz, A. A. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2728-6 · Cited by 1,377
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
Cho, S. W., Kim, S., Kim, Y., Kweon, J., Kim, H. S., Bae, S., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.162339.113 · Cited by 1,356
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“One of the studies using hESC-derived RPE also reported an improvement of vision in patients with age-related macular degeneration as well as those with Stargardt disease [218].”
ResultEnhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
PTC124 targets genetic disorders caused by nonsense mutations
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,137
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Diversity and evolution of class 2 CRISPR–Cas systems
Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.184 · Cited by 1,029
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
New microRNAs from mouse and human
LAGOS-QUINTANA, M., RAUHUT, R., MEYER, J., BORKHARDT, A., & TUSCHL, T. (2003) · RNA · doi:10.1261/rna.2146903 · Cited by 909 · cited 1×
“Some miRNAs are commonly expressed in all retinal cell types while others are specifically expressed in one or the other [5,129], suggesting that there are possibilities to employ these molecules therapeutically.”
BackgroundOcular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Next-Generation Optical Technologies for Illuminating Genetically Targeted Brain Circuits
Deisseroth, K., Feng, G., Majewska, A. K., Miesenböck, G., Ting, A., & Schnitzer, M. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3863-06.2006 · Cited by 812
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772 · cited 1×
“However, its limited cargo capacity hampers an efficient delivery of the complete CRISPR/Cas9 system [73].”
BackgroundDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 6×
“AAV7m8 serotype was generated by in vivo directed evolution in the mouse retina by Dalkara and collaborators [193,195].”
BackgroundInfluentialWill Retinal Implants Restore Vision?
Zrenner, E. (2002) · Science · doi:10.1126/science.1067996 · Cited by 724
In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14500 · Cited by 715
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Mutations in the CEP290 (NPHP6) Gene Are a Frequent Cause of Leber Congenital Amaurosis
den Hollander, A. I., Koenekoop, R. K., Yzer, S., Lopez, I., Arends, M. L., Voesenek, K. E. J., Zonneveld, M. N., Strom, T. M., Meitinger, T., Brunner, H. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507318 · Cited by 668
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Lamba, D. A., Gust, J., & Reh, T. A. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.10.015 · Cited by 603
The molecular basis of human retinal and vitreoretinal diseases
Berger, W., Kloeckener-Gruissem, B., & Neidhardt, J. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.03.004 · Cited by 594
The Microbial Opsin Family of Optogenetic Tools
Zhang, F., Vierock, J., Yizhar, O., Fenno, L. E., Tsunoda, S., Kianianmomeni, A., Prigge, M., Berndt, A., Cushman, J., Polle, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.12.004 · Cited by 509
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Restoration of vision after transplantation of photoreceptors
Pearson, R. A., Barber, A. C., Rizzi, M., Hippert, C., Xue, T., West, E. L., Duran, Y., Smith, A. J., Chuang, J. Z., Azam, S. A., et al. (2012) · Nature · doi:10.1038/nature10997 · Cited by 493
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Kaur, C., Foulds, W. S., & Ling, E. A. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.003 · Cited by 470
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
Auricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Song, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393
Athanasiou, D., Aguila, M., Bellingham, J., Li, W., McCulley, C., Reeves, P. J., & Cheetham, M. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.002 · Cited by 373
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
A library of TAL effector nucleases spanning the human genome
Kim, Y., Kweon, J., Kim, A., Chon, J. K., Yoo, J. Y., Kim, H. J., Kim, S., Lee, C., Jeong, E., Chung, E., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2517 · Cited by 370
Five-year safety and performance results from the argus II retinal prosthesis system clinical trial.
da Cruz, L., Dorn, J. D., Humayun, M. S., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., Safran, A. B., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.049 · Cited by 359
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345
The mammalian photoreceptor mosaic-adaptive design
Ahnelt, P. K., & Kolb, H. (2000) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00012-4 · Cited by 334
Homology-mediated end joining-based targeted integration using CRISPR/Cas9
Yao, X., Wang, X., Hu, X., Liu, Z., Liu, J., Zhou, H., Shen, X., Wei, Y., Huang, Z., Ying, W., et al. (2017) · Cell Research · doi:10.1038/cr.2017.76 · Cited by 333
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies
Sohocki, M. M., Daiger, S. P., Bowne, S. J., Rodriquez, J. A., Northrup, H., Heckenlively, J. R., Birch, D. G., Mintz-Hittner, H., Ruiz, R. S., Lewis, R. A., et al. (2001) · Human Mutation · doi:10.1002/1098-1004(2001)17:1<42::aid-humu5>3.0.co;2-k · Cited by 329
Pearson, R. A., Gonzalez-Cordero, A., West, E. L., Ribeiro, J. R., Aghaizu, N., Goh, D., Sampson, R. D., Georgiadis, A., Waldron, P. V., Duran, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13029 · Cited by 309
Parfitt, D. A., Lane, A., Ramsden, C. M., Carr, A.-J. F., Munro, P. M., Jovanovic, K., Schwarz, N., Kanuga, N., Muthiah, M. N., Hull, S., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.03.021 · Cited by 301
Gold Nanoparticles: Recent Advances in the Biomedical Applications
Zhang, X. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0529-4 · Cited by 299
Sakami, S., Maeda, T., Bereta, G., Okano, K., Golczak, M., Sumaroka, A., Roman, A. J., Cideciyan, A. V., Jacobson, S. G., & Palczewski, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209759 · Cited by 291
Repair of the degenerate retina by photoreceptor transplantation
Barber, A. C., Hippert, C., Duran, Y., West, E. L., Bainbridge, J. W. B., Warre-Cornish, K., Luhmann, U. F. O., Lakowski, J., Sowden, J. C., Ali, R. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212677110 · Cited by 280
A computational study of off-target effects of RNA interference
Qiu, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki324 · Cited by 274
Retinal transplantation of photoreceptors results in donor–host cytoplasmic exchange
Santos-Ferreira, T., Llonch, S., Borsch, O., Postel, K., Haas, J., & Ader, M. (2016) · Nature Communications · doi:10.1038/ncomms13028 · Cited by 273
Retinal stimulation strategies to restore vision: fundamentals and systems
Yue, L., Weiland, J. D., Roska, B., & Humayun, M. S. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.05.002 · Cited by 272 · cited 10×
“Subretinal prostheses (ASR, IMS/AMS, PRIMA and BSI) are placed between the degenerated photoreceptor layer and the RPE, such that the intrinsic signal processing capability of the retinal interneurons can be used optimally, generating vision similar to the one that is physiologically generated in the eye [84,222].”
BackgroundResultInfluentialOptogenetic tools for analyzing the neural circuits of behavior
Bernstein, J. G., & Boyden, E. S. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.10.003 · Cited by 270
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
RNA interference: concept to reality in crop improvement
Saurabh, S., Vidyarthi, A. S., & Prasad, D. (2014) · Planta · doi:10.1007/s00425-013-2019-5 · Cited by 249
Sermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., Vermeulen, F., Leal, T., Mogenet, A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0137oc · Cited by 248
Stem cell treatment of degenerative eye disease
Mead, B., Berry, M., Logan, A., Scott, R. A. H., Leadbeater, W., & Scheven, B. A. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.02.003 · Cited by 237
Clinical Characteristics and Current Therapies for Inherited Retinal Degenerations
Sahel, J.-A., Marazova, K., & Audo, I. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 232
Koizumi, H., Spaide, R. F., Fisher, Y. L., Freund, K. B., Klancnik, J. M., & Yannuzzi, L. A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.014 · Cited by 228
Cideciyan, A. V., Jacobson, S. G., Drack, A. V., Ho, A. C., Charng, J., Garafalo, A. V., Roman, A. J., Sumaroka, A., Han, I. C., Hochstedler, M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0295-0 · Cited by 222
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213 · cited 1×
“With this, therapeutic agents are delivered directly to the suprachoroidal space located between the sclera and choroid [175,176].”
BackgroundLe Meur, G., Stieger, K., Smith, A. J., Weber, M., Deschamps, J. Y., Nivard, D., Mendes-Madeira, A., Provost, N., Péréon, Y., Cherel, Y., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302861 · Cited by 207
Advances in retinal prosthesis systems
Bloch, E., Luo, Y., & da Cruz, L. (2019) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418817501 · Cited by 201 · cited 7×
“Subretinal prostheses (ASR, IMS/AMS, PRIMA and BSI) are placed between the degenerated photoreceptor layer and the RPE, such that the intrinsic signal processing capability of the retinal interneurons can be used optimally, generating vision similar to the one that is physiologically generated in the eye [84,222].”
BackgroundInfluentialNudelman, I., Rebibo-Sabbah, A., Cherniavsky, M., Belakhov, V., Hainrichson, M., Chen, F., Schacht, J., Pilch, D. S., Ben-Yosef, T., & Baasov, T. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801640k · Cited by 190
Sangermano, R., Garanto, A., Khan, M., Runhart, E. H., Bauwens, M., Bax, N. M., van den Born, L. I., Khan, M. I., Cornelis, S. S., Verheij, J. B. G. M., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0414-9 · Cited by 190
Self-citationVitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 1×
“Liposomes however also present some limitations such as retinal toxicity and aggregation following administration [208].”
BackgroundWeiland, J. D., & Humayun, M. S. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2314733 · Cited by 186
Precision genome editing in the CRISPR era
Salsman, J., & Dellaire, G. (2017) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0137 · Cited by 185
Cronin, T., Vandenberghe, L. H., Hantz, P., Juttner, J., Reimann, A., Kacsó, Á., Huckfeldt, R. M., Busskamp, V., Kohler, H., Lagali, P. S., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404077 · Cited by 184
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
Sengupta, A., Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampič, M., Forster, V., Marre, O., Lin, J. Y., Sahel, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505699 · Cited by 180
Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications
Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., Tahir, N., Ijaz, S., Al-Kassas, R., & Löbenberg, R. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3cp55 · Cited by 176
RNA Interference–Mediated Suppression and Replacement of Human Rhodopsin In Vivo
O’Reilly, M., Palfi, A., Chadderton, N., Millington-Ward, S., Ader, M., Cronin, T., Tuohy, T., Auricchio, A., Hildinger, M., Tivnan, A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519025 · Cited by 173
Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171
Remondelli, P., & Renna, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00187 · Cited by 169
Genetic therapies for RNA mis-splicing diseases
Hammond, S. M., & Wood, M. J. A. (2011) · Trends in Genetics · doi:10.1016/j.tig.2011.02.004 · Cited by 165
Latella, M. C., Di Salvo, M. T., Cocchiarella, F., Benati, D., Grisendi, G., Comitato, A., Marigo, V., & Recchia, A. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.92 · Cited by 165
Dulla, K., Aguila, M., Lane, A., Jovanovic, K., Parfitt, D. A., Schulkens, I., Chan, H. L., Schmidt, I., Beumer, W., Vorthoren, L., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.07.010 · Cited by 165
Self-citationGenome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration
Kim, K., Park, S. W., Kim, J. H., Lee, S. H., Kim, D., Koo, T., Kim, K.-E., Kim, J. H., & Kim, J.-S. (2017) · Genome Research · doi:10.1101/gr.219089.116 · Cited by 163
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation
Moreno, A. M., Fu, X., Zhu, J., Katrekar, D., Shih, Y.-R. V., Marlett, J., Cabotaje, J., Tat, J., Naughton, J., Lisowski, L., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.017 · Cited by 159
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
An RNA–Deaminase Conjugate Selectively Repairs Point Mutations
Stafforst, T., & Schneider, M. F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206489 · Cited by 154
Xue, X., Mutyam, V., Tang, L., Biswas, S., Du, M., Jackson, L. A., Dai, Y., Belakhov, V., Shalev, M., Chen, F., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0282oc · Cited by 154
Bauwens, M., Garanto, A., Sangermano, R., Naessens, S., Weisschuh, N., Zaeytijd, J. D., Khan, M., Sadler, F., Balikova, I., Cauwenbergh, C. V., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0420-y · Cited by 153
Self-citationPrecision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells
Bassuk, A. G., Zheng, A., Li, Y., Tsang, S. H., & Mahajan, V. B. (2016) · Scientific Reports · doi:10.1038/srep19969 · Cited by 150
Gene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149 · cited 1×
“So far, AAV2 is the only vector described to transduce retinal ganglion cells upon intravitreal delivery [191,192].”
BackgroundOptogenetic Vision Restoration Using Rhodopsin for Enhanced Sensitivity
Gaub, B. M., Berry, M. H., Holt, A. E., Isacoff, E. Y., & Flannery, J. G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.121 · Cited by 147
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Burnight, E. R., Gupta, M., Wiley, L. A., Anfinson, K. R., Tran, A., Triboulet, R., Hoffmann, J. M., Klaahsen, D. L., Andorf, J. L., Jiao, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.015 · Cited by 142
Robson, A. G., El-Amir, A., Bailey, C., Egan, C. A., Fitzke, F. W., Webster, A. R., Bird, A. C., & Holder, G. E. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1278 · Cited by 141
Albert, S., Garanto, A., Sangermano, R., Khan, M., Bax, N. M., Hoyng, C. B., Zernant, J., Lee, W., Allikmets, R. L., Collin, R. W. J., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.02.008 · Cited by 139
Self-citationMendes, H. F., & Cheetham, M. E. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn202 · Cited by 137
Collin, R. W., den Hollander, A. I., van der Velde-Visser, S. D., Bennicelli, J., Bennett, J., & Cremers, F. P. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.3 · Cited by 137
Self-citationNudelman, I., Atia-Glikin, D., Smolkin, B., Hainrichson, M., Белахов, В. В., & Baasov, T. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.060 · Cited by 136
Slijkerman, R. W., Vaché, C., Dona, M., García-García, G., Claustres, M., Hetterschijt, L., Peters, T. A., Hartel, B. P., Pennings, R. J., Millan, J. M., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.89 · Cited by 134
Self-citationDefining the Integration Capacity of Embryonic Stem Cell-Derived Photoreceptor Precursors
West, E. L., Gonzalez-Cordero, A., Hippert, C., Osakada, F., Martínez-Barberá, J. P., Pearson, R. A., Sowden, J. C., Takahashi, M., & Ali, R. R. (2012) · Stem Cells · doi:10.1002/stem.1123 · Cited by 133
The suprachoroidal space as a route of administration to the posterior segment of the eye
Chiang, B., Jung, J. H., & Prausnitz, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.001 · Cited by 130
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 127
Evolutionary Insights into RNA trans-Splicing in Vertebrates
Lei, Q., Li, C., Zuo, Z., Huang, C., Cheng, H., & Zhou, R. (2016) · Genome Biology and Evolution · doi:10.1093/gbe/evw025 · Cited by 126
AAV-mediated CRISPR/cas gene editing of retinal cells in vivo
Hung, S. S. C., Chrysostomou, V., Li, F., Lim, J. K. H., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19316 · Cited by 125
Duebel, J., Marazova, K., & Sahel, J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000140 · Cited by 122
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120 · cited 1×
“Other vectors under study are lentiviruses and nanoparticles, which have larger cargo capacities [28].”
BackgroundHarnessing human ADAR2 for RNA repair – Recoding a PINK1 mutation rescues mitophagy
Wettengel, J., Reautschnig, P., Geisler, S., Kahle, P. J., & Stafforst, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw911 · Cited by 120
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Schwarz, N., Carr, A. F., Lane, A., Möller, F., Chen, L., Aguilà, M., Nommiste, B., Muthiah, M. N., Kanuga, N., Wolfrum, U., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu509 · Cited by 118
Vighi, E., Trifunović, D., Veiga-Crespo, P., Rentsch, A., Hoffmann, D. B., Sahaboglu, A., Straßer, T., Kulkarni, M. M., Bertolotti, E., van den Heuvel, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718792115 · Cited by 116
Kumar-Singh, R., & Farber, D. B. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.12.1893 · Cited by 113
Fischer, M. D., McClements, M. E., Martinez-Fernandez de la Camara, C., Bellingrath, J.-S., Dauletbekov, D., Ramsden, S. C., Hickey, D. G., Barnard, A. R., & MacLaren, R. E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.005 · Cited by 112 · cited 1×
“This requirement can for instance be improved by varying the serotypes of AAVs that are used to deliver the transgene [31–33], by varying the promoter sequence [30] or by producing codon-optimized cDNA versions of a given gene [34,35].”
BackgroundImmune response following intraocular delivery of recombinant viral vectors
Bennett, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302030 · Cited by 111
Retinoids for treatment of retinal diseases
Palczewski, K. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.03.001 · Cited by 111 · cited 2×
“The efficacy of gentamicin was studied in different rat and mouse models—(i) the S334ter rat model that carries a nonsense mutation (c.1002T>A; p.S334*) in the gene encoding the visual pigment rhodopsin (Rho) and (ii) the rd12 mouse, a model for retinal degeneration caused by a nonsense mutation in Rpe65.”
BackgroundHagiwara, A., Yamamoto, S., Ogata, K., Sugawara, T., Hiramatsu, A., Shibata, M., & Mitamura, Y. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.01866.x · Cited by 110
Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)
Nagel‐Wolfrum, K., Möller, F., Penner, I., Baasov, T., & Wolfrum, U. (2016) · BioDrugs · doi:10.1007/s40259-016-0157-6 · Cited by 110
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 110
Self-citationLiu, Y., Xu, H. W., Wang, L., Li, S. Y., Zhao, C. J., Hao, J., Li, Q. Y., Zhao, T. T., Wu, W., Wang, Y., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0053-y · Cited by 110
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Optogenetic approaches to vision restoration
Simunovic, M. P., Shen, W., Lin, J. Y., Protti, D. A., Lisowski, L., & Gillies, M. C. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2018.09.003 · Cited by 109
Gerard, X., Perrault, I., Hanein, S., Silva, E., Bigot, K., Defoort-Delhemmes, S., Rio, M., Munnich, A., Scherman, D., Kaplan, J., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.21 · Cited by 106
Alternative splicing and retinal degeneration
Liu, M. M., & Zack, D. J. (2013) · Clinical Genetics · doi:10.1111/cge.12181 · Cited by 105
Murray, S. F., Jazayeri, A., Matthes, M. T., Yasumura, D., Yang, H., Peralta, R., Watt, A., Freier, S., Hung, G., Adamson, P. S., et al. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16400 · Cited by 105
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Tauroursodeoxycholic Acid Prevents Retinal Degeneration in Transgenic P23H Rats
Fernández-Sánchez, L., Lax, P., Pinilla, I., Martín-Nieto, J., & Cuenca, N. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7496 · Cited by 103
Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye.
Einmahl, S., Savoldelli, M., D'Hermies, F., Tabatabay, C., Gurny, R., & Béhar‐Cohen, F. (2002) · PubMed · Cited by 102
Bergelson, J. M., Modlin, J. F., Wieland‐Alter, W., Cunningham, J. A., Crowell, R. L., & Finberg, R. W. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.3.697 · Cited by 102
Goldmann, T., Overlack, N., Möller, F., Belakhov, V., van Wyk, M., Baasov, T., Wolfrum, U., & Nagel‐Wolfrum, K. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201438 · Cited by 102
CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa
Wu, W.-H., Tsai, Y.-T., Justus, S., Lee, T.-T., Zhang, L., Lin, C.-S., Bassuk, A. G., Mahajan, V. B., & Tsang, S. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.107 · Cited by 99
The Nature of Dominant Mutations of Rhodopsin and Implications for Gene Therapy
Wilson, J. H., & Wensel, T. G. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:2:149 · Cited by 96
Ghosh, A., Yue, Y., & Duan, D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.122 · Cited by 95
Berger, A., Lorain, S., Joséphine, C., Desrosiers, M., Peccate, C., Voit, T., Garcia, L., Sahel, J.-A., & Bemelmans, A.-P. (2015) · Molecular Therapy · doi:10.1038/mt.2015.11 · Cited by 92
Goldstein, D. A., Do, D., Noronha, G., Kissner, J. M., Srivastava, S. K., & Nguyen, Q. D. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.6.14 · Cited by 91
Mangos, M., Min, K., Viazovkina, E., Galarneau, A., Elzagheid, M. I., Parniak, M. A., & Damha, M. J. (2002) · Journal of the American Chemical Society · doi:10.1021/ja025557o · Cited by 90
Nudelman, I., Rebibo-Sabbah, A., Shallom-Shezifi, D., Hainrichson, M., Stahl, I., Ben‐Yosef, T., & Baasov, T. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.013 · Cited by 90
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
Georgiadis, A., Duran, Y., Ribeiro, J., Abelleira-Hervas, L., Robbie, S. J., Sünkel-Laing, B., Fourali, S., Gonzalez-Cordero, A., Cristante, E., Michaelides, M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.66 · Cited by 84 · cited 1×
“This requirement can for instance be improved by varying the serotypes of AAVs that are used to deliver the transgene [31–33], by varying the promoter sequence [30] or by producing codon-optimized cDNA versions of a given gene [34,35].”
BackgroundRetinal miRNA Functions in Health and Disease
Žužić, M., Arias, J. E. R., Wohl, S. G., & Busskamp, V. (2019) · Genes · doi:10.3390/genes10050377 · Cited by 84
Shimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
Zhong, H., Chen, Y., Li, Y., Chen, R., & Mardon, G. (2015) · Scientific Reports · doi:10.1038/srep08366 · Cited by 81
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80 · cited 1×
“For IRDs, gene augmentation is currently the most advanced therapeutic strategy, with market approval for one gene (RPE65, LuxturnaTM), several ongoing clinical studies for other genes (Table 1) and preclinical development for a plethora of genes mutated in these diseases [36].”
BackgroundA Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer
Guerra, E., Trerotola, M., Dell' Arciprete, R., Bonasera, V., Palombo, B., El-Sewedy, T., Ciccimarra, T., Crescenzi, C., Lorenzini, F., Rossi, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6135 · Cited by 79
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
Ocular gene therapy: a review of nonviral strategies.
Andrieu‐Soler, C., Bejjani, R. A., de Bizemont, T., Normand, N., BenEzra, D., & Béhar‐Cohen, F. (2006) · PubMed · Cited by 77
Moosajee, M., Tracey-White, D., Smart, M., Weetall, M., Torriano, S., Kalatzis, V., da Cruz, L., Coffey, P., Webster, A. R., & Welch, E. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw184 · Cited by 77
Rebibo-Sabbah, A., Nudelman, I., Ahmed, Z. M., Baasov, T., & Ben‐Yosef, T. (2007) · Human Genetics · doi:10.1007/s00439-007-0410-7 · Cited by 76
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01326-0 · Cited by 76
Glaus, E., Schmid, F. M., Costa, R. D., Berger, W., & Neidhardt, J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.7 · Cited by 75
Gene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
Schmid, F. M., Glaus, E., Barthelmes, D., Fliegauf, M., Gaspar, H., Nürnberg, G., Nürnberg, P., Omran, H., Berger, W., & Neidhardt, J. (2011) · Human Mutation · doi:10.1002/humu.21509 · Cited by 74
Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73
Design of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 72
Baye, L. M., Patrinostro, X., Swaminathan, S., Beck, J. S., Zhang, Y., Stone, E. M., Sheffield, V. C., & Slusarski, D. C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr025 · Cited by 71
Scholl, H. P. N., Moore, A. T., Koenekoop, R. K., Wen, Y., Fishman, G. A., van den Born, L. I., Bittner, A., Bowles, K., Fletcher, E. C., Collison, F. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143846 · Cited by 71 · cited 2×
“The safety profile of this drug showed transient adverse effects such as headaches or nausea [171].”
BackgroundGene Therapy, Early Promises, Subsequent Problems, and Recent Breakthroughs
Soofiyani, S. R., Baradaran, B., Lotfipour, F., Kazemi, T., & Mohammadnejad, L. (2013) · PubMed · doi:10.5681/apb.2013.041 · Cited by 70
Ameri, H. (2018) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2018.01.006 · Cited by 70
Anand, V., Duffy, B., Yang, Z., Dejneka, N. S., Maguire, A. M., & Bennett, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0525 · Cited by 69 · cited 1×
“In other words, the introduction of a foreign antigen (like a viral vector) is generally well tolerated without evoking severe inflammatory responses [4,5].”
BackgroundCashman, S. M., Sadowski, S. L., Morris, D. J., Frederick, J., & Kumar-Singh, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0806 · Cited by 68
Intraocular Delivery of Recombinant Virus
Liang, F.-Q., Anand, V., Maguire, A. M., & Bennett, J. (2003) · Vision Research Protocols · doi:10.1385/1-59259-085-3:125 · Cited by 68
Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS
Boyer, D., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., et al. (2002) · Pure Amsterdam UMC · Cited by 68
Garanto, A., Duijkers, L., Tomkiewicz, T. Z., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10060452 · Cited by 66
Self-citationSafety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01332-6 · Cited by 65
Requirements for gene silencing mediated by U1 snRNA binding to a target sequence
Abad, X., Vera, M., Jung, S. P., Oswald, E., Romero‐Brey, I., Amin, V., Fortes, P., & Gunderson, S. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn068 · Cited by 63
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63 · cited 1×
“Carvalho and collaborators characterized an in silico designed serotype named Anc80 for retinal gene transfer [196].”
BackgroundLow, B. E., Krebs, M. P., Joung, J. K., Tsai, S. Q., Nishina, P. M., & Wiles, M. V. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13278 · Cited by 62
Unexpected CEP290 mRNA Splicing in a Humanized Knock-In Mouse Model for Leber Congenital Amaurosis
Garanto, A., van Beersum, S. E. C., Peters, T. A., Roepman, R., Cremers, F. P. M., & Collin, R. W. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079369 · Cited by 62
Self-citationSmith, J., Ward, D., Michaelides, M., Moore, A. T., & Simpson, S. (2015) · Eye · doi:10.1038/eye.2015.115 · Cited by 61
Gene-based therapies for dominantly inherited retinopathies
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Humphries, P., & Kenna, P. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.172 · Cited by 61
A novel zinc-finger nuclease platform with a sequence-specific cleavage module
Schierling, B., Dannemann, N., Gabsalilow, L., Wende, W., Cathomen, T., & Pingoud, A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1112 · Cited by 60
Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA
Tanner, G., Glaus, E., Barthelmes, D., Ader, M., Fleischhauer, J. C., Pagani, F., Berger, W., & Neidhardt, J. (2008) · Human Mutation · doi:10.1002/humu.20861 · Cited by 59
Parfitt, D. A., Aguila, M., McCulley, C. H., Bevilacqua, D., Mendes, H. F., Athanasiou, D., Novoselov, S. S., Kanuga, N., Munro, P. M., Coffey, P. J., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.214 · Cited by 59
Jo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57
Diakatou, M., Manes, G., Bocquet, B., Meunier, I., & Kalatzis, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102542 · Cited by 57
Beneficial Read-Through of a USH1C Nonsense Mutation by Designed Aminoglycoside NB30 in the Retina
Goldmann, T., Rebibo-Sabbah, A., Overlack, N., Nudelman, I., Белахов, В. В., Baasov, T., Ben‐Yosef, T., Wolfrum, U., & Nagel‐Wolfrum, K. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5741 · Cited by 54
Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1
Bonifert, T., González-Menéndez, I., Battke, F., Theurer, Y., Synofzik, M., Schöls, L. J., & Wissinger, B. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.93 · Cited by 54
Nonviral ocular gene therapy: assessment and future directions.
Conley, S. M., Cai, X., & Naash, M. I. (2008) · PubMed · Cited by 52
Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa
Guerin, K. I., Gregory, C. Y., Hodges, M., Moosajee, M., Mackay, D. S., Gregory-Evans, K., & Flannery, J. G. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.05.016 · Cited by 52
Ryoo, N.-K., Lee, J., Lee, H., Hong, H. K., Kim, H., Lee, J. B., Woo, S. J., Park, K. H., & Kim, H. (2017) · Nanoscale · doi:10.1039/c7nr03142d · Cited by 52
Kong, F., Li, W., Li, X., Zheng, Q., Dai, X., Zhou, X., Boye, S. L., Hauswirth, W. W., Qu, J., & Pang, J.-J. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.01.011 · Cited by 51
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
Tolone, A., Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2019) · Genes · doi:10.3390/genes10060453 · Cited by 51
Boyer, D., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., et al. (2002) · Pure Amsterdam UMC · Cited by 45
In Vitro Gene Delivery in Retinal Pigment Epithelium Cells by Plasmid DNA-Wrapped Gold Nanoparticles
Trigueros, S., B. Domènech, E., Toulis, V., & Marfany, G. (2019) · Genes · doi:10.3390/genes10040289 · Cited by 45
Li, N., Zheng, J., Li, H., Deng, J., Hu, M., Wu, H., Li, W., Li, F., Lan, X., Lü, J., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu201 · Cited by 44
Mallam, J. N., Hurwitz, M. Y., Mahoney, T., Che´vez-Barrios, P., & Hurwitz, R. L. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0730 · Cited by 43
Gene Augmentation for adRP Mutations in RHO
Lewin, A. S., Rossmiller, B., & Mao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017400 · Cited by 43
Honcharenko, D., Barman, J., Varghese, O. P., & CHATTOPADHYAYA, J. B. (2007) · Biochemistry · doi:10.1021/bi0620205 · Cited by 42
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 42
Garanto, A., van der Velde-Visser, S. D., Cremers, F. P. M., & Collin, R. W. J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_11 · Cited by 41
Self-citationA Gene Therapeutic Approach to Correct Splice Defects with Modified U1 and U6 snRNPs
Schmid, F. M., Hiller, T., Korner, G., Glaus, E., Berger, W., & Neidhardt, J. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.110 · Cited by 40
iPS Cells for Modelling and Treatment of Retinal Diseases
Chen, F. K., McLenachan, S., Edel, M. J., da Cruz, L., Coffey, P. J., & Mackey, D. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3041511 · Cited by 38
Ocular gene therapy: A review of non-viral strategies
Andrieu‐Soler, C., Bejjani, R. A., de Bizemont, T., Normand, N., BenEzra, D., & Béhar‐Cohen, F. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.011 · Cited by 38
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“…another subtype of inherited retinal disease that is caused by bi-allelic mutations in RPE65, has provided hope for many visually impaired individuals, and is paralleled by the development of similar therapeutic strategies for other genes underlying these disorders (Vazquez-Dominguez et al., 2019).”
BackgroundSelf-citationPontikos, N., Arno, G., Jurkute, N., Schiff, E., Ba-Abbad, R., Malka, S., Gimenez, A., Georgiou, M., Wright, G., Armengol, M., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.008 · Cited by 254
“Adenoassociated viruses have been a vector of choice for ocular gene therapy trials, targeting retinal cells with relatively low immunogenicity, but their capacity is limited.(5) We explored transcript lengths and relationships with numbers of families affected.”
BackgroundInfluentialHerrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
“Luxturna has established the safety and efficacy of gene augmentation via subretinal delivery, and, now, many different AAV gene therapies are under preclinical and/or clinical development (7, 8).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
Self-citation
Metadata
- Authors
- Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J.
- Affiliations
- Radboud University Nijmegen (NL)
- Corresponding author
- Garanto, Alejandro
- Collin, Rob W. J.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-08-28
- Volume
- 10
- Issue
- 9
- Pages
- 654
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6770110
- OpenAlex
- W2971284229
- Cited by
- 80
- References
- 235
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 19 · 2021: 24 · 2020: 11 · 2019: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (PPA-0517-0717-RAD)
- UitZicht (2015-31, 2018-21)
- ZonMw (Off Road 91215203)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- inherited retinal disease, gene therapy, gene augmentation therapy, RPE65, genome editing, optogenetics, RNA therapeutics, retinal degeneration, molecular therapy
- MeSH terms
- Clinical Trials as Topic, Humans, Retinal Degeneration, Genetic Therapy, Gene Transfer Techniques, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.